Aptus Endosystems, a Sunnyvale, Calif.-based company that develops technology for endovascular aneurysm repair, has closed a $25m equity financing.
The round was led by Synergy Life Science Partners, with participation from existing investors US Venture Partners and Longitude Capital Management. In conjunction with the investment, Mudit K. Jain, Ph.D., Partner at Synergy Life Science Partners, will join the company’s Board of Directors.
Aptus intends to use thw proceeds from the financing to expand commercialization of the HeliFX™ Aortic Securement System in the United States and Europe, where the company has already obtained US Food and Drug Administration (FDA) clearance and CE Mark, respectively.
Led by James Reinstein, President and CEO, the company will also develop further HeliFX product offerings to fulfill unmet needs in the treatment of aortic aneurysms. In addition, it plans to execute a US clinical trial of the Fortevo™ AAA Endograft System in support of filing for Premarket Approval with the FDA. Lastly, Aptus will expand utilization of the Fortevo system in key European centers, where it already possesses the CE Mark.